CIBC Private Wealth Group
BBIO icon

CIBC Private Wealth Group’s BridgeBio Pharma BBIO Stock Holding History

CIBC Private Wealth Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$693K Buy
9,061
+1,302
+17% +$85.5K ﹤0.01% 785
2025
Q3 		$403K Buy
7,759
+6,156
+384% +$300K ﹤0.01% 933
2025
Q2 		$69.2K Sell
1,603
-1,697
-51% -$61.7K ﹤0.01% 1540
2025
Q1 		$99.5K Buy
3,300
+1,500
+83% +$50.6K ﹤0.01% 1359
2024
Q4 		$53K Hold
1,800
– – ﹤0.01% 1663
2024
Q3 		$45.8K Buy
1,800
+1,000
+125% +$26.3K ﹤0.01% 1808
2024
Q2 		$20.9K Hold
800
– – ﹤0.01% 2010
2024
Q1 		$24K Buy
+800
New +$27.2K ﹤0.01% 1977

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Private Wealth Group's BBIO Position: Q4 2025 in Review

CIBC Private Wealth Group increased its BridgeBio Pharma (BBIO) stake by 17% in Q4 2025, buying an estimated $85.5K and bringing the position to 9,061 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #785.

CIBC Private Wealth Group first reported a position in BBIO in Q1 2024 and has held it in 8 quarters since. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • CIBC Private Wealth Group held 9,061 shares of BridgeBio Pharma worth $693K as of Q4 2025.
  • CIBC Private Wealth Group bought 1,302 BridgeBio Pharma shares in Q4 2025, an estimated $85.5K.
  • BridgeBio Pharma made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #785 holding.
  • CIBC Private Wealth Group first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 8 quarters since.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.